{"contentid": 488601, "importid": NaN, "name": "MiNA Therapeutics picks up another saRNA research deal", "introduction": "MiNA Therapeutics has today announced a global research collaboration with US pharma major Eli Lilly to develop novel drug candidates using MiNA\u00e2\u0080\u0099s proprietary small activating RNA (saRNA) technology platform.", "content": "<p>Adding to a deal with AstraZeneca (LSE: AZN) in 2020 and one with Servier earlier this year, UK-based RNA activation therapeutics pioneer MiNA Therapeutics has today announced a global research collaboration with US pharma major Eli Lilly (NYSE: LLY) to develop novel drug candidates using MiNA&rsquo;s proprietary small activating RNA (saRNA) technology platform.</p>\n<p>Under the terms of the accord, privately-held MiNA will utilize its saRNA platform to research up to five targets selected by Lilly that aim to address diseases across Lilly&rsquo;s key therapeutic focus areas. Lilly will be responsible for pre-clinical and clinical development of candidates and will retain exclusive commercialization rights for any products resulting from the collaboration.&nbsp;</p>\n<h2><strong>Financial terms of the accord</strong></h2>\n<p>MiNA will receive a $25 million upfront payment and is eligible to receive potential development and commercialization milestones up to a total of $245 million per target, as well as tiered royalties from the low-single to low-double digits on&nbsp;product sales resulting from the collaboration. The global research deal could be worth up to $1.25 billion to MiNA, a spokesperson for the company noted.</p>\n<p>&ldquo;Small activating RNAs are a promising new technology, which will expand the breadth of Lilly&rsquo;s RNA therapeutics platform and the targets we can pursue,&rdquo; said Andrew Adams, vice president for new therapeutic modalities at Lilly. &ldquo;We are excited about the potential of combining MiNA&rsquo;s leading saRNA platform and our expertise in new modalities to accelerate development of RNA-based medicines in areas of high unmet medical need,&rdquo; he noted.</p>\n<p>&ldquo;This collaboration with Lilly is an important validation of our saRNA platform,&rdquo; said Robert Habib, chief executive of MiNA Therapeutics, adding: &ldquo;Lilly&rsquo;s expertise in the field of RNA therapeutics and clinical development will greatly enhance our efforts to realize the technology&rsquo;s full potential. Together, we aim to unlock new targets in multiple therapeutic areas and to ultimately move them towards clinical development and commercialization.&rdquo;</p>\n<p>This transaction will be reflected in Lilly&rsquo;s reported results and financial guidance according to Generally Accepted Accounting Principles (GAAP). There will be no change to Lilly&rsquo;s 2021 non-GAAP earnings per share guidance as a result of this transaction, the US firm said.</p>", "date": "2021-05-11 16:33:00", "meta_title": "MiNA Therapeutics picks up another saRNA research deal", "meta_keywords": "MiNA Therapeutics, Eli Lilly,  saRNA research, Collaboration", "meta_description": "MiNA Therapeutics picks up another saRNA research deal", "meta_robots": NaN, "meta_display_in_sitemap": 1, "canonical_url": NaN, "status": 1, "access_status": 0, "ignore_flexible_sampling": 0, "display_start_date": "0000-00-00 00:00:00", "display_end_date": "0000-00-00 00:00:00", "display_in_search": 1, "created": "2021-05-11 16:31:18", "updated": "2021-05-11 16:41:09", "access": NaN, "url": "https://www.thepharmaletter.com/article/mina-therapeutics-picks-up-another-sarna-research-deal", "description": NaN, "twitter_term": NaN, "twitter_widgetid": NaN, "key_facts": NaN, "news_snippet": NaN, "image1id": "mina_large.jpg", "image2id": "mina_small.jpg", "restrict_print": 0, "restrict_print_for_logged_out": 0, "box1_header": NaN, "box1_title": NaN, "box1_image1id": 0, "box1_url": NaN, "box1_introduction": NaN, "box1_position": 0, "tags": NaN, "sector_tag": "Biotechnology", "therapy area_tag": NaN, "topic_tag": "Deals, Licensing, Research", "geography_tag": "UK, USA", "company_tag": "Eli Lilly, MiNA Therapeutics", "drug_tag": NaN, "market index_tag": NaN, "theme_tag": NaN, "industry sector_tag": NaN, "medical condition_tag": NaN, "industry term_tag": NaN, "organization_tag": NaN, "person_tag": NaN, "position_tag": NaN, "medical treatment_tag": NaN, "facility_tag": NaN, "technology_tag": NaN, "journalist_tag": NaN, "published medium_tag": NaN, "political event_tag": NaN, "anniversary_tag": NaN, "sports event_tag": NaN, "movie_tag": NaN, "fax number_tag": NaN, "currency pair_tag": NaN, "sports league_tag": NaN, "date_tag": NaN, "music group_tag": NaN, "phone number_tag": NaN, "t v show_tag": NaN, "t v station_tag": NaN, "entertainment award event_tag": NaN, "industry_tag": NaN, "pharmaceutical drug_tag": NaN, "topmost public parent company_tag": NaN, "content_type_name": "Article", "pubDate": "2021-05-11 16:33:00"}